Reni et al compared basal CA 19-9 serum levels in 247 advanced p

Reni et al. compared basal CA 19-9 serum levels in 247 advanced pancreatic cancer patients enrolled in 5 consecutive chemotherapy trials (G, gemcitabine; PEFG, cisplatin, epirubicin, 5-fluorouracil, and gemcitabine; PDXG, cisplatin, docetaxel, capecitabine, and gemcitabine) (60). The survival curves were plotted based on a pre-defined decline in CA 19-9 serum levels (Group 1, <50% decrease, Group 2, 50% to 89% decrease and Group 3, >89% decrease). Patients with a higher percent decline in CA 19-9 serum level

following treatment had improved overall survival (Group III-16.7 Lapatinib datasheet months compared to Group II-10 months, P=0.002, Inhibitors,research,lifescience,medical and Group II- 10 months vs. 6.5 months for Group -I, P=0.002). Overall, the median survival was Inhibitors,research,lifescience,medical 15.5 months among patients with normal CA 19-9 levels, 11.9 months

among 108 patients with CA 19-9 serum levels between 38 U/mL and 1167 U/mL and 8 months among 105 patients who had CA 19-9 serum levels >1167 U/mL (60). Table 5 CA 19-9 serum levels are a reliable marker of chemotherapy response. A CA 19-9 serum levels which decreases to ≤20-50% of baseline levels within the first 6-8 weeks of treatment Inhibitors,research,lifescience,medical predicts prolonged survival and is an independent predictor of overall … Halm et al. evaluated CA 19-9 serum levels in 36 patients enrolled in gemcitabine chemotherapy trials and reported that patients with a decline in CA 19-9 serum levels of >20% from baseline after 8 weeks of treatment (n=25) had improved median survival compared to patients with a rise Inhibitors,research,lifescience,medical or a decrease of <20% (n=11) (268 vs. 110 days, P=0.001) (55). Moreover, treatment related decline in CA 19-9 serum levels was the strongest independent predictor of survival (P<0.001) on multivariate analysis. Finally, using a novel approach to compute log CA 19-9 kinetics among 115 patients enrolled in first line pancreatic cancer chemotherapy, Inhibitors,research,lifescience,medical Boeck et al. Histone demethylase demonstrated

that log CA 19-9 kinetics was a significant predictor of both time to tumor progression (Hazard Ratio, HR 1.48, P<0.001) and overall survival (HR 1.34, P<0.001) (66). Utility of CA 19-9 serum levels to predict post-operative recurrence The predictive value of current methods (CT scan and PET scan) to assess early post-operative recurrence is sub-optimal given that pancreatic resection is often associated with intense desmoplastic and post-operative inflammatory changes leading to dense fibrosis making radiological detection difficult (15,41,60). The utility of sequential post-operative CA 19-9 serum level measurement to detect early recurrence in pancreatic cancer patients has been well studied. Kang et al.

Related posts:

  1. Cetuximab is a monoclonal antibody (MoAb) against the ligand-bind
  2. Lithium’s reduction of IP3 levels therefore inhibits calcium rele
  3. Odds and hazard ratios are provided with their 95% confidence int
  4. 080) and ideational praxis score (P = 0 061) On the contrary, no
  5. , with no cardiac event reported [70] Different schedules and do
This entry was posted in Antibody. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>